A new wave of pharmaceutical research is challenging the long-held assumption that sleep apnea can only be managed with cumbersome machines and mouthguards. An epilepsy drug called sulthiame has shown striking results in a large clinical trial published in The Lancet in March 2026, reducing breathing interruptions during sleep by up to 47 percent compared to placebo. Meanwhile, a first-in-class oral pill known as AD109 is nearing FDA submission after two successful Phase 3 trials, and an already-approved obesity medication called Zepbound has become the first prescription drug cleared specifically for obstructive sleep apnea in adults with obesity. For the millions of people who abandon their CPAP machines within the first year — estimates suggest roughly half of users do — these developments represent a genuine shift in treatment possibilities.
The connection between sleep apnea and brain health makes this research particularly urgent for anyone concerned about dementia and cognitive decline. Obstructive sleep apnea fragments sleep architecture, starves the brain of oxygen repeatedly throughout the night, and has been linked in numerous longitudinal studies to elevated risks of Alzheimer’s disease and vascular dementia. A pill that effectively reduces apnea events could, in theory, protect the brain during its most critical repair window. This article examines the three drugs currently generating the most attention, what the clinical data actually shows, who these treatments might help, and what limitations and safety concerns patients should weigh before assuming a simple pill will replace their CPAP.
Table of Contents
- What Sleep Apnea Drugs Are Under Investigation and What Does the New Research Show?
- How AD109 Could Become the First FDA-Approved Oral Sleep Apnea Pill
- Zepbound and the Obesity-Apnea Connection
- Comparing the Three Options — Which Drug Fits Which Patient?
- Why Brain Health Advocates Should Watch Sleep Apnea Drug Trials Closely
- CPAP Remains the Standard — Where Pills Fit In
- What Comes Next in Sleep Apnea Pharmacotherapy
- Conclusion
- Frequently Asked Questions
What Sleep Apnea Drugs Are Under Investigation and What Does the New Research Show?
The most talked-about finding comes from the FLOW study, a multicenter, randomized, double-blind, placebo-controlled trial that tested sulthiame across 28 sites in five European countries. Researchers enrolled 298 adult patients with untreated moderate-to-severe obstructive sleep apnea and assigned them to one of three doses — 100 mg, 200 mg, or 300 mg — taken once daily at bedtime for 15 weeks. The results were notable: higher doses reduced breathing interruptions by up to 47 percent compared to placebo, with the 200 mg and 300 mg doses reducing overall OSA severity by approximately 30 to 50 percent. To put that in concrete terms, patients in the highest-dose group saw their apnea-hypopnea index drop from 55.2 events per hour down to 33.0 events per hour, a 41 percent reduction. Placebo patients, by contrast, saw only a 5.4 percent decline.
Sulthiame works differently from CPAP or oral appliances. Rather than mechanically holding the airway open, the drug stabilizes the body’s control of breathing and increases respiratory drive, reducing the tendency for the upper airway to collapse during sleep. This pharmacological approach is appealing because it addresses one of the root neurological mechanisms behind obstructive sleep apnea rather than just managing its physical symptoms. Side effects in the trial were mostly mild and temporary, which is encouraging, though the 15-week study duration leaves open questions about long-term safety and whether the benefits hold over months or years of continuous use. For comparison, CPAP therapy — when used consistently — can reduce the AHI to below 5 events per hour in most patients, essentially normalizing breathing. Sulthiame brought AHI down substantially but not to that level, which means it may work best for patients with moderate apnea or as a complement to other treatments rather than a standalone replacement for severe cases.
How AD109 Could Become the First FDA-Approved Oral Sleep Apnea Pill
The experimental drug AD109, developed by Apnimed, takes a different pharmacological approach. It combines two medications in a single once-daily oral pill that stimulate the muscles responsible for keeping the airway open during sleep. Two Phase 3 trials have now reported positive results. The SynAIRgy trial showed a mean AHI reduction of 55.6 percent from baseline at 26 weeks across patients with mild, moderate, and severe obstructive sleep apnea. The LunAIRo trial, a 12-month study, demonstrated a 46.8 percent AHI reduction at week 26 compared to just 6.8 percent with placebo, and the benefit remained statistically significant at week 51. What stands out about the LunAIRo data is the durability. At week 26, 45 percent of participants had improved disease severity classification, and that figure actually ticked up slightly to 47.5 percent at week 51.
Roughly 22 to 23 percent of participants achieved complete disease control, defined as an AHI below 5, at both the 26-week and 51-week marks. Apnimed plans to file a new Drug Application with the FDA in early 2026, and with a standard review period of approximately 10 months, the drug could reach the market by early 2027. However, patients should understand the limitations. A 55 percent reduction in AHI is meaningful, but it also means nearly half of breathing disturbances persist. If someone has severe sleep apnea with an AHI of 60, a 55 percent reduction would bring them to around 27 — still in the moderate range. The most common side effects reported were dry mouth and insomnia, both mild or moderate in severity, and no serious adverse events related to AD109 were reported in the trials. But insomnia as a side effect of a sleep apnea drug is worth watching carefully, especially for patients whose cognitive health depends on restorative sleep.
Zepbound and the Obesity-Apnea Connection
The FDA approved Zepbound, the brand name for tirzepatide, on December 20, 2024, making it the first and only prescription medicine approved specifically for adults with moderate-to-severe obstructive sleep apnea who also have obesity. This approval acknowledged something clinicians have long known: excess body weight is one of the strongest drivers of obstructive sleep apnea, and losing weight can dramatically reduce or even resolve the condition. In clinical trials, Zepbound reduced AHI by 25.3 events per hour in one study and 29.3 events per hour in another, compared to reductions of only 5.3 and 5.5 events per hour with placebo. The practical example here is instructive. Consider a patient with an AHI of 40 and a body mass index of 38. CPAP would address the breathing disturbances directly but leave the underlying obesity untreated.
Zepbound tackles the root cause — the excess weight compressing the airway — which means the apnea improvement may persist even without nightly device use. For patients with dementia risk factors, this dual benefit of weight loss and improved sleep breathing could be particularly relevant, since obesity itself is an independent risk factor for cognitive decline. The tradeoffs, though, are significant. Zepbound is an injection, not a pill. Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, fatigue, and hair loss. More seriously, the drug carries warnings about thyroid tumors including cancer, pancreatitis, gallbladder problems, acute kidney injury, and suicidal behavior or thinking. It also only applies to patients who are both obese and have sleep apnea — the roughly 20 to 30 percent of apnea patients who are not obese would not be candidates.
Comparing the Three Options — Which Drug Fits Which Patient?
Each of these three drugs addresses a different piece of the sleep apnea puzzle, and no single option is clearly superior for all patients. Sulthiame targets the neurological control of breathing and showed a 41 percent AHI reduction at the highest dose, making it potentially useful for patients whose apnea stems from unstable respiratory drive rather than pure anatomical obstruction. AD109 works on airway muscle tone and achieved the largest AHI reductions in trials — up to 55.6 percent — and has the advantage of being a once-daily pill with relatively mild side effects. Zepbound attacks the obesity-driven component of sleep apnea and produced AHI reductions of 25 to 29 events per hour, but its benefit is limited to patients who are both obese and have OSA. The tradeoff between efficacy and side effect burden is worth examining closely. Sulthiame was well tolerated with mostly mild and temporary side effects, but data beyond 15 weeks does not yet exist.
AD109 had a favorable safety profile over 12 months, though dry mouth and insomnia are relevant concerns. Zepbound has the most robust efficacy data as an already-approved drug but carries the most serious safety warnings, including the risk of thyroid tumors. For older adults already managing multiple medications — a common scenario in dementia caregiving — the interaction profile and side effect burden of any new drug matters enormously. A reasonable way to think about this: patients with obesity-driven apnea who can tolerate injections might benefit most from Zepbound. Patients with moderate apnea who refuse or cannot tolerate CPAP could be candidates for sulthiame or AD109, pending approvals. None of these drugs have been tested specifically for their effects on dementia risk or cognitive outcomes, which remains a critical gap in the research.
Why Brain Health Advocates Should Watch Sleep Apnea Drug Trials Closely
The link between obstructive sleep apnea and dementia is not speculative. Repeated oxygen desaturation during sleep damages blood vessels in the brain, promotes neuroinflammation, accelerates amyloid plaque accumulation, and disrupts the glymphatic system that clears metabolic waste during deep sleep. Studies have shown that people with untreated sleep apnea develop cognitive impairment at higher rates and at earlier ages than matched controls. Treating apnea with CPAP has been associated with slower cognitive decline in some observational studies, though the landmark DREAM trial in 2023 did not show a clear dementia prevention benefit from CPAP in older adults with mild apnea. The limitation that matters here is this: none of the three drugs discussed in this article were designed or tested with cognitive outcomes as endpoints.
The clinical trials measured AHI reduction, symptom improvement, and safety — not whether participants developed fewer biomarkers of Alzheimer’s disease or performed better on memory tests over time. A drug that reduces AHI by 50 percent but fails to restore deep sleep architecture might have a very different cognitive impact than one that reduces AHI by 30 percent but allows patients to spend more time in slow-wave sleep. These are distinctions that will take years of additional research to clarify. Patients and caregivers should also be cautious about assuming that partial AHI reductions will translate to meaningful brain protection. If a drug brings someone from severe apnea to moderate apnea, they are still experiencing dozens of oxygen desaturation events every hour. Whether that partial improvement is sufficient to slow neurodegeneration is genuinely unknown.
CPAP Remains the Standard — Where Pills Fit In
It is worth stating plainly that CPAP, when used consistently, remains more effective at eliminating sleep apnea events than any of these drugs. A well-fitted CPAP machine can reduce AHI to below 5 in the vast majority of patients. The problem has never been CPAP’s efficacy — it is adherence.
Studies consistently show that 30 to 50 percent of patients abandon CPAP within the first year due to discomfort, claustrophobia, dry mouth, mask leaks, and the general inconvenience of sleeping while tethered to a machine. For caregivers managing someone with dementia, CPAP presents additional challenges. Patients with cognitive impairment may remove the mask during the night, resist wearing it, or become agitated by the sensation. A pill taken at bedtime sidesteps these issues entirely, which is why even a drug that achieves only moderate AHI reduction could have outsized practical value in this population.
What Comes Next in Sleep Apnea Pharmacotherapy
The next 12 to 18 months will be pivotal. Apnimed’s anticipated NDA filing for AD109 in early 2026 should trigger an FDA review process that could yield a decision by early 2027. If approved, AD109 would become the first oral medication specifically developed and indicated for obstructive sleep apnea, regardless of weight status.
Additional trials of sulthiame with longer follow-up periods and larger sample sizes are expected, and researchers will likely explore whether combining pharmacotherapy with lower-pressure CPAP could achieve better results than either approach alone. For the dementia research community, the most important next step would be trials that measure cognitive outcomes directly. A well-designed study tracking biomarkers of neurodegeneration in patients treated with these new drugs versus CPAP versus no treatment could fundamentally change how we think about sleep apnea as a modifiable dementia risk factor. Until that data exists, the most honest thing to say is that these drugs look promising for sleep apnea itself, and there are strong biological reasons to believe that treating apnea protects the brain, but we do not yet have proof that any specific pill prevents or slows dementia.
Conclusion
The landscape of sleep apnea treatment is undergoing a genuine transformation. Sulthiame demonstrated up to a 47 percent reduction in breathing interruptions in a rigorous European trial, AD109 achieved a 55.6 percent AHI reduction and is heading toward FDA review, and Zepbound is already available for patients with both obesity and sleep apnea. Each drug has distinct mechanisms, benefits, and limitations, and none fully replaces CPAP for severe cases. But for the enormous population of patients who cannot or will not use CPAP — including many older adults with cognitive impairment — a bedtime pill that meaningfully reduces apnea events represents a practical breakthrough.
Anyone considering these options should discuss them with a sleep medicine specialist and, if applicable, a neurologist. The connection between sleep apnea and dementia risk is well-established enough that leaving moderate-to-severe apnea untreated is a gamble with long-term brain health. Whether the right solution is CPAP, a new medication, weight loss, or a combination, the worst option is doing nothing. These new drugs will not solve every case, but they significantly expand the toolkit available to patients and clinicians who have been waiting for alternatives.
Frequently Asked Questions
Is there an FDA-approved pill for sleep apnea?
Not yet. Zepbound (tirzepatide), approved in December 2024, treats sleep apnea in patients who also have obesity, but it is an injection, not a pill. AD109, a once-daily oral pill from Apnimed, is expected to be submitted for FDA approval in early 2026, with a potential market availability by early 2027.
How does sulthiame treat sleep apnea if it was designed for epilepsy?
Sulthiame stabilizes the body’s control of breathing and increases respiratory drive, which reduces the tendency for the upper airway to collapse during sleep. This mechanism happens to address one of the core neurological contributors to obstructive sleep apnea, even though the drug was originally developed for seizure disorders.
Can sleep apnea drugs reduce my risk of dementia?
There are strong biological reasons to believe that treating sleep apnea — by any method — may help protect the brain, since untreated apnea is associated with oxygen deprivation, neuroinflammation, and accelerated amyloid buildup. However, none of the current sleep apnea drug trials have measured dementia outcomes directly, so this remains an area of active research rather than established fact.
What are the side effects of the new sleep apnea drugs?
Sulthiame’s side effects in the FLOW trial were mostly mild and temporary. AD109’s most common side effects were dry mouth and insomnia, with no serious adverse events reported. Zepbound carries more significant warnings including nausea, vomiting, risk of thyroid tumors, pancreatitis, and suicidal thinking. Each drug’s risk profile should be weighed against the known harms of untreated sleep apnea.
Will these drugs replace CPAP machines?
Unlikely for severe cases. CPAP can reduce AHI to below 5 events per hour in most patients, while the best drug results so far show 41 to 55 percent reductions — meaningful but not equivalent. These drugs may be most valuable for patients who refuse or cannot tolerate CPAP, or as a complement to lower-pressure CPAP therapy.
Are these drugs safe for elderly patients with dementia?
The clinical trials did not specifically enroll patients with dementia, so there is no direct safety data for this population. Older adults often take multiple medications, increasing the risk of drug interactions. Any decision to use these medications in someone with cognitive impairment should involve both a sleep specialist and the patient’s neurologist or geriatrician.
